MX9205922A - Composiciones de sales de antibiotico lipofilico oligosacarido. - Google Patents

Composiciones de sales de antibiotico lipofilico oligosacarido.

Info

Publication number
MX9205922A
MX9205922A MX9205922A MX9205922A MX9205922A MX 9205922 A MX9205922 A MX 9205922A MX 9205922 A MX9205922 A MX 9205922A MX 9205922 A MX9205922 A MX 9205922A MX 9205922 A MX9205922 A MX 9205922A
Authority
MX
Mexico
Prior art keywords
antibiotic
matter
formula iii
compounds
amount
Prior art date
Application number
MX9205922A
Other languages
English (en)
Spanish (es)
Inventor
David Loebenberg
James B Morton
George H Miller
Heewon Y Kwon
Mahesh Patel
Vincent P Gullo
Roberta Hare
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX9205922A publication Critical patent/MX9205922A/es

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/08Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04Heterocyclic radicals containing only oxygen as ring hetero atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08Hetero rings containing eight or more ring members, e.g. erythromycins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/02Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
    • C07H9/04Cyclic acetals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
MX9205922A 1991-10-16 1992-10-15 Composiciones de sales de antibiotico lipofilico oligosacarido. MX9205922A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77786491A 1991-10-16 1991-10-16

Publications (1)

Publication Number Publication Date
MX9205922A true MX9205922A (es) 1994-08-31

Family

ID=25111545

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9205922A MX9205922A (es) 1991-10-16 1992-10-15 Composiciones de sales de antibiotico lipofilico oligosacarido.

Country Status (26)

Country Link
US (1) US5624914A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (2) EP0538011B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2614407B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100249584B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1035923C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE156019T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU678344B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2121345C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE69221252T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0538011T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2104845T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI941723A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR3024800T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (1) HRP921069B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUT75157A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL103446A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX9205922A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO307326B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ244735A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH31675A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL170591B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI9200260A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW221378B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1993007904A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
YU (1) YU48722B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA927923B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6380172B1 (en) 1991-10-16 2002-04-30 Schering Corporation Monomeric lipophilic oligosaccharide antibiotic compositions
US5948688A (en) * 1991-10-16 1999-09-07 Schering Corporation Method of determining monomeric drug content
US5652226A (en) * 1995-12-22 1997-07-29 Schering Corporation Water soluble antibiotics
US5776912A (en) * 1996-12-20 1998-07-07 Schering Corporation Lipophilic oligosaccharide antibiotic compositions
US5763600A (en) * 1997-04-18 1998-06-09 Schering Corporation Oligosaccharide antibiotics and process for preparation thereof
JP2001518556A (ja) * 1997-10-03 2001-10-16 ガレニカ ファーマシューティカルズ, インコーポレイテッド イミン形成ポリサッカライド、その調製、ならびにアジュバントおよび免疫刺激剤としてのその使用
US6162910A (en) * 1998-11-30 2000-12-19 Schering Corporation Process for preparing lipophilic oligosaccharide antibiotics
AU2157200A (en) * 1998-12-18 2000-07-12 Schering Corporation Process for recovering lipophilic oligosaccharide antibiotics
US6320044B1 (en) 1998-12-18 2001-11-20 Schering Corporation Process for recovering lipophilic oligosaccharide antibiotics
AU2003201A (en) * 1999-12-01 2001-06-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel use of lung surfactant
US6861513B2 (en) 2000-01-12 2005-03-01 Schering Corporation Everninomicin biosynthetic genes
CA2726789A1 (en) * 2000-02-05 2001-11-08 Theravance, Inc. Cyclodextrin containing glycopeptide antibiotic compositions
WO2002032459A2 (en) * 2000-10-17 2002-04-25 Massachusetts Institute Of Technology Method of increasing the efficacy of antibiotics by complexing with cyclodextrins
DE10109166A1 (de) * 2001-02-25 2002-09-12 Combinature Biopharm Ag Avilamycin-Derivate
CA2560266A1 (en) * 2004-03-17 2005-09-29 Panacos Pharmaceuticals, Inc. Pharmaceutical salts of 3-o-(3',3'-dimethylsuccinyl) betulinic acid
EP1977874A3 (en) * 2004-12-01 2008-10-15 Nitto Denko Corporation Foam Filling Member
WO2006110810A2 (en) * 2005-04-12 2006-10-19 Panacos Pharmaceuticals, Inc. Polymorphs of 3-o-(3',3'-dimethylsuccinyl) betulinic acid di-n-methyl-d-glucamine
AU2008299885C1 (en) * 2007-09-14 2015-06-25 Sanofi Pasteur Biologics, Llc Pharmaceutical compositions containing clostridium difficile toxoids A and B
JP2010095454A (ja) * 2008-10-14 2010-04-30 Cyclochem:Kk 抗菌組成物
WO2012097223A2 (en) * 2011-01-14 2012-07-19 Emory University Oligosaccharide conjugates for targeting bacteria and uses related thereto
JP2018517046A (ja) 2015-06-10 2018-06-28 ビテス, インコーポレイテッド ヒドロキシプロピル−ベータ−シクロデキストリン組成物および方法
CN106317143B (zh) * 2016-08-23 2020-10-30 河北圣雪大成制药有限责任公司 一种提取阿维拉霉素的方法
CN118922484A (zh) 2022-02-18 2024-11-08 贝伦治疗公益公司 羟丙基-β-环糊精的组合物和其纯化方法
CN117024611B (zh) * 2023-03-01 2024-05-17 中国科学院南海海洋研究所 寡糖类抗生素everninomicin高产菌株的构建及活性的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR128F (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1962-04-02
US3915956A (en) * 1973-07-09 1975-10-28 Schering Corp Reduction products of everninomicins and methods for their manufacture
US3920629A (en) * 1973-09-19 1975-11-18 Schering Corp Desevernitrose everninomicins and method for their manufacture
US4006225A (en) * 1973-10-31 1977-02-01 Schering Corporation Method of using reduction products of everninomicins as antibacterial agents and pharmaceutical compositions useful therefor
US4027016A (en) * 1976-01-19 1977-05-31 Schering Corporation Everninomicin antibacterial derivatives, electrochemical method for their manufacture, method for their use as antibacterial agents, and pharmaceutical compositions useful therefor
US3998708A (en) * 1976-01-19 1976-12-21 Schering Corporation Electrochemical process for preparing hydroxylaminoeverninomicins
US4129720A (en) * 1977-02-14 1978-12-12 Schering Corporation Aminoeverninomicin and derivatives thereof
US4597968A (en) * 1982-08-06 1986-07-01 Schering Corporation Antibiotic 13-384 complex from Micromonospora carbonacea var africana
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4735903A (en) * 1984-06-21 1988-04-05 Schering Corporation Micromonospora carbonacea var africana
US4870060A (en) * 1985-03-15 1989-09-26 Janssen Pharmaceutica Derivatives of γ-cylodextrin
US4622314A (en) * 1985-10-15 1986-11-11 Schering Corporation Substituted oligosaccharide antibiotics
US4767748A (en) * 1985-10-15 1988-07-30 Schering Corporation Substituted oligosaccharide antibodies
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5017566A (en) * 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도

Also Published As

Publication number Publication date
SI9200260A (en) 1993-06-30
HK1001085A1 (en) 1998-05-22
YU92192A (sr) 1996-01-09
ES2104845T3 (es) 1997-10-16
AU2780692A (en) 1993-05-21
GR3024800T3 (en) 1998-01-30
NO307326B1 (no) 2000-03-20
PL170591B1 (pl) 1997-01-31
JPH06510546A (ja) 1994-11-24
FI941723A7 (fi) 1994-04-14
ATE156019T1 (de) 1997-08-15
HUT75157A (en) 1997-04-28
DE69221252D1 (de) 1997-09-04
AU678344B2 (en) 1997-05-29
YU48722B (sh) 1999-07-28
WO1993007904A1 (en) 1993-04-29
EP0538011B1 (en) 1997-07-30
IL103446A (en) 1997-02-18
DE69221252T2 (de) 1998-01-22
FI941723A0 (fi) 1994-04-14
DK0538011T3 (da) 1997-09-08
NZ244735A (en) 1995-12-21
EP0610295A1 (en) 1994-08-17
HU9401104D0 (en) 1994-07-28
EP0538011A1 (en) 1993-04-21
TW221378B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1994-03-01
NO941276L (no) 1994-04-08
CN1035923C (zh) 1997-09-24
HRP921069B1 (en) 1999-12-31
ZA927923B (en) 1993-04-26
CA2121345A1 (en) 1993-04-29
IL103446A0 (en) 1993-03-15
PH31675A (en) 1999-01-18
CA2121345C (en) 1998-08-25
CN1073359A (zh) 1993-06-23
NO941276D0 (no) 1994-04-08
KR100249584B1 (ko) 2000-04-01
JP2614407B2 (ja) 1997-05-28
HRP921069A2 (en) 1994-12-31
US5624914A (en) 1997-04-29

Similar Documents

Publication Publication Date Title
MX9205922A (es) Composiciones de sales de antibiotico lipofilico oligosacarido.
UY26635A1 (es) Métodos sinérgicos y composiciones para el tratamiento del cáncer
MX9307555A (es) Derivados de paclitaxel y formulaciones farmaceuticas que los contienen.
MX9202407A (es) Composicion farmaceutica que contiene un compuesto de alilamina como el agente activo y proceso para su preparacion.
ITRM920361A0 (it) Composizioni farmaceutiche contenenti un composto allilamminico quale principio attivo.
AR006678A1 (es) Derivados de macrolidas triciclicas, una composicion farmaceutica que los contiene, uso de los mismos para preparar medicamentos y procedimientopara su preparacion
NO20100302L (no) Sammensetninger som inneholder organiske forbindelser
MA22522A1 (fr) Procede de formulation de compositions pharmaceutiques
ITBO910113A1 (it) Formulazioni farmaceutiche per uso orale gastroresistenti contenenti acidi biliari.
NZ244021A (en) Benzylthiazolidinedione derivatives, preparation and pharmaceutical compositions thereof
IL101358A0 (en) Crystalline tiagabine hydrochloride monohydrate,its preparation and pharmaceutical compositions containing it
ES2092646T3 (es) Metanoantracenos como antagonistas de dopamina.
PE3096A1 (es) Formulacion conteniendo selenio
ES2173883T3 (es) Utilizacion de derivados de piperacina-acetamida contra los daños de reperfusion.
ATE290858T1 (de) N-palmitoylethanolamid-enthaltende pharmazeutische zusammensetzungen und deren verwendung in der veterinärmedizin
IT1301968B1 (it) Derivati di eritromicina ad attivita' antibiotica
ATE107853T1 (de) Orales, melatonin enthaltendes arzneimittel.
DK0673376T3 (da) Bicykliske pyrimidinforbindelser, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som omfatter dem
AR009251A1 (es) Compuestos de ácido 4-oxo-butanoico y composiciones que los contienen
ES2092645T3 (es) Metanoantracenos como antagonistas de dopamina.
DK0521353T3 (da) Lægemiddel med antineoplastisk virkning, der som virksomt stof indeholder octadecyl-(2-(N-metylpiperidino)-ethyl)-phosphat og fremgangsmåde til fremstilling deraf
ATE234096T1 (de) Pharmazeutische zusammensetzung zur systemischen transdermalen verabreichung mit dem wirkstoff morphin-6-glucuronid
ES2053880T3 (es) Utilizacion de derivados de adenosina en la preparacion de composiciones farmaceuticas que poseen actividad inmunoestimulante.
AR028699A1 (es) Nueva formulacion
AR038847A1 (es) Uso del compuesto n-(3,5-dicloro-2-metoxi-fenil) -4-metoxi-3-piperazin-1-il-bencenosulfonamida para la elaboracion de una composicion farmaceutica y dicha composicion farmaceutica

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees